Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Change in Receivables (2018 - 2024)

Historic Change in Receivables for Serina Therapeutics (SER) over the last 7 years, with Q1 2024 value amounting to -$163000.0.

  • Serina Therapeutics' Change in Receivables fell 8953.49% to -$163000.0 in Q1 2024 from the same period last year, while for Jun 2024 it was $673000.0, marking a year-over-year increase of 33206.9%. This contributed to the annual value of $554000.0 for FY2023, which is 273809.52% up from last year.
  • Per Serina Therapeutics' latest filing, its Change in Receivables stood at -$163000.0 for Q1 2024, which was down 8953.49% from $175000.0 recorded in Q4 2023.
  • Serina Therapeutics' 5-year Change in Receivables high stood at $661000.0 for Q3 2023, and its period low was -$196000.0 during Q2 2023.
  • Moreover, its 5-year median value for Change in Receivables was -$11000.0 (2020), whereas its average is $16000.0.
  • In the last 5 years, Serina Therapeutics' Change in Receivables tumbled by 365000.0% in 2020 and then surged by 610909.09% in 2023.
  • Over the past 5 years, Serina Therapeutics' Change in Receivables (Quarter) stood at $124000.0 in 2020, then plummeted by 99.19% to $1000.0 in 2021, then surged by 200.0% to $3000.0 in 2022, then surged by 5733.33% to $175000.0 in 2023, then tumbled by 193.14% to -$163000.0 in 2024.
  • Its last three reported values are -$163000.0 in Q1 2024, $175000.0 for Q4 2023, and $661000.0 during Q3 2023.